Duchenne muscular dystrophy (DMD) is diagnosed through a combination of blood tests, genetic testing, and sometimes muscle biopsy, though genetic testing is now the primary confirmatory tool. Despite available tests, the average age at diagnosis remains around 5 years for boys without a family history, often two years after parents first notice something is off.
Early Signs That Raise Suspicion
Parents are typically the first to notice something unusual, with the average age of first concern around 30 months. A toddler who is slow to walk, struggles to keep up with peers, falls frequently, or has difficulty climbing stairs may prompt a visit to the pediatrician. One hallmark sign is the Gowers’ maneuver, where a child uses their hands to “walk up” their own legs when standing from the floor, compensating for weak hip and thigh muscles.
Enlarged calf muscles are another early clue. The calves look muscular but are actually swollen with fatty and scar tissue replacing healthy muscle. Some boys also show speech or language delays before motor problems become obvious, which can sometimes steer early evaluations away from a neuromuscular diagnosis and contribute to the delay.
The Blood Test That Comes First
The first diagnostic step is a simple blood test measuring creatine kinase (CK), an enzyme that leaks out of damaged muscle cells. A person without DMD typically has CK levels below 200 units per liter. Boys with Duchenne often have levels 10 to 100 times that normal range, sometimes reaching 10,000 to 20,000 or higher. A dramatically elevated CK level doesn’t confirm DMD on its own, since other muscle conditions can raise CK too, but it’s a strong signal that something is wrong with the muscles and warrants further testing.
Notably, when elevated CK is the initial finding (sometimes caught incidentally through other bloodwork), diagnosis tends to happen earlier, around 25 months of age on average, compared to 30 months when developmental delay is the first concern. This highlights how a straightforward blood draw can shave months off the diagnostic timeline.
Genetic Testing Confirms the Diagnosis
Once CK levels point toward a muscle disease, genetic testing is the next and most important step. DMD is caused by mutations in the dystrophin gene, the largest gene in the human body, located on the X chromosome. The goal of genetic testing is to identify the specific mutation, which matters not just for confirming the diagnosis but also for determining which treatments might be available.
About 68% of patients have a deletion, meaning a chunk of the gene is missing. Around 11% have a duplication, where a section is copied an extra time. The remaining 20% or so have smaller mutations, like single-letter changes in the genetic code. In fewer than 1% of cases, rarer mutations are responsible, such as deep intronic changes that trick the cell’s machinery into misreading instructions.
Testing usually starts with a technique called MLPA, which is good at detecting the large deletions and duplications that account for roughly 80% of cases. If that comes back negative but suspicion remains high, next-generation sequencing of the entire dystrophin gene can catch the smaller point mutations and insertions that MLPA misses.
When Muscle Biopsy Is Needed
Genetic testing identifies the mutation in the vast majority of cases, so muscle biopsy is no longer routine. But when genetic results are inconclusive, a biopsy can provide the answer. A small sample of muscle tissue is examined under a microscope for two things: the structural health of the muscle fibers and the presence (or absence) of the dystrophin protein.
In DMD, dystrophin is virtually absent from the muscle membrane. Healthy muscle fibers are replaced by a disorganized mix of damaged, dying, and regenerating fibers interspersed with fat and scar tissue. A related protein called utrophin is often upregulated, essentially the body’s attempt to compensate for the missing dystrophin. This pattern on biopsy is distinctive enough to confirm a dystrophinopathy even when genetic testing hasn’t pinpointed a mutation.
Distinguishing Duchenne From Becker
Duchenne and Becker muscular dystrophy (BMD) are caused by mutations in the same gene, so telling them apart matters. The key difference comes down to whether the mutation completely destroys the dystrophin protein or just shortens it. In Duchenne, the mutation disrupts the gene’s reading frame, meaning the cell can’t produce any functional dystrophin. In Becker, the reading frame stays intact, so a shorter but partially functional protein is made.
On muscle biopsy, boys with Duchenne show virtually no dystrophin, while those with Becker retain 10% to 40% of the normal amount. Clinically, the distinction shows up in the timeline: boys with Duchenne typically need a wheelchair before age 13, while those with Becker remain walking past 16. Genetic testing can often predict which form a child has based on whether the mutation shifts the reading frame, though there are exceptions to this rule.
Baseline Functional Assessments
Once a diagnosis is confirmed, clinicians establish a baseline of the child’s physical abilities. The most widely used tool is the North Star Ambulatory Assessment, a standardized set of 17 activities (standing from the floor, walking, climbing steps, hopping) scored on a simple scale. This isn’t part of the diagnostic process itself, but it begins at diagnosis and serves as the yardstick for tracking progression over time.
Other baseline measurements include timed tests like how quickly a child can walk or run 10 meters and how fast they can rise from the floor. These numbers help predict the trajectory of motor function over the next several years and inform decisions about starting treatment.
Testing Female Family Members
Because DMD is X-linked, a new diagnosis in a boy has immediate implications for his mother and sisters. About two-thirds of mothers are carriers, meaning they have one working copy and one mutated copy of the dystrophin gene. The remaining third of cases arise from new, spontaneous mutations.
Carrier testing follows the same genetic approach used for the affected child: MLPA first to look for deletions and duplications, followed by sequencing if needed. CK levels in carriers can be mildly elevated but aren’t reliable enough on their own for detection. Female relatives of confirmed carriers are also recommended for testing, since knowing carrier status affects reproductive planning and, in some cases, personal health. A small percentage of female carriers develop cardiac or mild muscle symptoms themselves.
Newborn Screening on the Horizon
In December 2025, the U.S. Department of Health and Human Services approved adding DMD to the Recommended Uniform Screening Panel, the federal list of conditions recommended for universal newborn screening. This is a significant shift. Currently, the average diagnostic delay from first parental concern to confirmed genetic diagnosis is nearly 26 months. Newborn screening could identify affected boys within days of birth, years before symptoms appear.
States choose whether to adopt each recommended screening, so availability will roll out gradually. But the addition to the panel signals a move toward catching DMD in infancy rather than waiting for a toddler to fall behind his peers, opening the door to earlier intervention during a window when muscle tissue is still relatively healthy.